Table 2.

ORs for seropositivity, DNA positivity, and combinations thereof, to HPV types 16, 18, 31, 33, 45, 52, and 58 among 648 female and 366 male university students by lifetime number of sexual partners

Lifetime number of sexual partnersnHPV antibodies*
HPV DNA
HPV antibodies or DNA
HPV antibodies and DNA
% + veOR (95% CI)% + veOR (95% CI)% + veOR (95% CI)% + veOR (95% CI)
Females
    038811.111.0111.910.31
    ≥115326.12.9 (1.8-4.7)12.714 (4.7-42)32.53.7 (2.3-5.8)6.426 (3.3-207)
        17126.82.9 (1.6-5.4)5.65.7 (1.4-24)31.03.3 (1.8-6.0)1.45.5 (0.3-89)
        2-34723.42.4 (1.2-5.2)17.020 (5.7-68)29.83.2 (1.6-6.3)10.646 (5.3-404)
        ≥43528.63.2 (1.4-7.1)22.928 (8.0-100)40.05.0 (2.4-10)11.450 (5.4-461)
        P for trend0.840.020.350.06
    Not reported10710.30.9 (0.5-1.8)2.82.8 (0.6-13)13.11.1 (0.6-2.1)0.0
Males
    012410.512.4112.910.0
    ≥120112.71.2 (0.6-2.5)3.91.6 (0.4-6.3)16.11.3 (0.7-2.5)0.5
        14415.91.6 (0.6-4.4)4.61.9 (0.3-12)18.21.5 (0.6-3.8)2.3
        2-36315.91.6 (0.7-3.9)3.21.3 (0.2-8.1)19.11.6 (0.7-3.6)0.0
        ≥4949.60.9 (0.4-2.2)4.31.8 (0.4-8.2)13.81.1 (0.5-2.4)0.0
    Not reported4112.21.2 (0.4-3.6)0.012.20.9 (0.3-2.7)0.0
  • * Restricted to women with valid HPV DNA results.

  • DNA refers to HPV types 16, 18, 31, 33, 45, 52, and 58.